<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013818</url>
  </required_header>
  <id_info>
    <org_study_id>HGS1029-C1080</org_study_id>
    <nct_id>NCT01013818</nct_id>
  </id_info>
  <brief_title>A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies</brief_title>
  <official_title>A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Human Genome Sciences Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients
      with relapsed or refractory lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type, frequency and severity of adverse events</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure pharmacokinetic profile</measure>
    <time_frame>1st two months of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacodynamics</measure>
    <time_frame>1st two months of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of possible anti-tumor activity</measure>
    <time_frame>Every 2 months while on study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Lymphoid Malignancies</condition>
  <arm_group>
    <arm_group_label>HGS1029</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGS1029</intervention_name>
    <description>HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.</description>
    <arm_group_label>HGS1029</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed relapsed/refractory lymphoid malignancies

          -  Previously treated with at least 2 therapeutic regimens

          -  ECOG performance &lt; 2.

          -  Life expectancy of at least 3 months

          -  Adequate renal function

          -  Adequate hematologic status

          -  Adequate liver function

          -  Transfusion independent

        Exclusion Criteria:

          -  Received other therapy (biological or drug) to treat cancer within 4 weeks prior to
             starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer
             treatment toxicity

          -  The use of systemic corticosteroids within 1 week of starting treatment with HGS1029

          -  Evidence of active bacterial, viral or fungal infection within 2 weeks before starting
             treatment with HGS1029

          -  Known HIV infection

          -  Positive for hepatitis B surface antigen or positive hepatitis C antibody

          -  Grade 2 or greater neuropathy

          -  Pregnant female or nursing mother

          -  Males or females who do not agree to use effective contraception during the study and
             through at least 30 days after the last dose of HGS1029
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Cancer and Haematology Centre</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute of Cancer Research</name>
      <address>
        <city>Belmont, Sutton, Surrey</city>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Centre</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

